Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.31 USD
-0.07 (-5.07%)
Updated Aug 6, 2025 03:55 PM ET
After-Market: $1.36 +0.05 (3.82%) 5:48 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BRNS 1.31 -0.07(-5.07%)
Will BRNS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BRNS
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
US Stocks Mixed; Bank of America Earnings Top Views
Barinthus Biotherapeutics Approves Key Proposals at AGM
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June ...